作者: R. Bryan Bell , Rom S. Leidner , Marka R. Crittenden , Brendan D. Curti , Zipei Feng
DOI: 10.1016/J.ORALONCOLOGY.2015.11.009
关键词: Pathology 、 Tumor necrosis factor alpha 、 Immunotherapy 、 CTLA-4 、 Head and neck cancer 、 Medicine 、 Cancer research 、 Tumor microenvironment 、 Immunosuppression 、 Head and neck squamous-cell carcinoma 、 Cancer
摘要: OX40 is a member of the tumor necrosis factor (TNF) receptor family and potent co-stimulatory pathway that when triggered can enhance T-cell memory, proliferation anti-tumor activity in patients with metastatic cancer. Ongoing investigations at our institution have demonstrated expressing T cells are found abundance tumors advanced stage head neck squamous cell carcinoma (HNSCC). This has led to initiation human clinical trials investigating OX40-directed therapy for HNSCC both curative setting. The purpose this review explore what known about signaling discuss how potentially be modulated improve outcome HNSCC.